Shares of Tesaro Inc. (NASDAQ:TSRO) dropped 2.1% on Tuesday . The company traded as low as $85.74 and last traded at $86.31, with a volume of 383,629 shares traded. The stock had previously closed at $88.20.

TSRO has been the topic of a number of recent research reports. Jefferies Group restated a “buy” rating on shares of Tesaro in a research note on Thursday, March 31st. Citigroup Inc. reiterated a “buy” rating and issued a $65.00 price target on shares of Tesaro in a research note on Thursday, March 17th. Leerink Swann reiterated a “buy” rating on shares of Tesaro in a research note on Monday, April 11th. Mizuho reiterated a “buy” rating and issued a $67.00 price target on shares of Tesaro in a research note on Wednesday, April 6th. Finally, FBR & Co reiterated a “buy” rating and issued a $65.00 price target on shares of Tesaro in a research note on Friday, May 6th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $73.91.

The firm has a 50 day moving average of $55.68 and a 200 day moving average of $45.30. The company’s market capitalization is $3.93 billion.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) EPS for the quarter, missing the consensus estimate of ($1.69) by $0.53. The company earned $0.31 million during the quarter, compared to analysts’ expectations of $2.48 million. During the same quarter in the previous year, the business earned ($1.30) earnings per share. On average, analysts anticipate that Tesaro Inc. will post ($7.11) EPS for the current year.

In related news, VP Edward C. English sold 7,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $40.75, for a total transaction of $285,250.00. Following the transaction, the vice president now directly owns 3,500 shares of the company’s stock, valued at approximately $142,625. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jeffrey H. Hanke sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $74.35, for a total value of $929,375.00. Following the transaction, the vice president now directly owns 12,500 shares in the company, valued at $929,375. The disclosure for this sale can be found here.

Other institutional investors recently added to or reduced their stakes in the company. American Century Companies Inc. raised its position in Tesaro by 6.7% in the fourth quarter. American Century Companies Inc. now owns 40,052 shares of the biopharmaceutical company’s stock valued at $2,096,000 after buying an additional 2,501 shares during the period. California State Teachers Retirement System raised its position in Tesaro by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,152 shares of the biopharmaceutical company’s stock valued at $2,258,000 after buying an additional 752 shares during the period. Nationwide Fund Advisors raised its position in Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 330 shares during the period. Jennison Associates LLC raised its position in Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock valued at $49,100,000 after buying an additional 574,041 shares during the period. Finally, Whittier Trust Co. raised its position in shares of Tesaro by 1.1% in the fourth quarter. Whittier Trust Co. now owns 20,945 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 220 shares during the last quarter.

TESARO, Inc (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.